Old disease, new targets part-I, solid malignancies

Shiyam Kumar, Nehal Masood, Asim Jamal Shaikh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Targeted agents are now an integral part of treatment regimens for some cancers. Trastuzumab is established in treatment of human epidermal receptor 2 (Her2) positive breast cancers, with improvements in both, the disease free and over all survival. Monoclonal antibody (MoAB) against vascular growth factor receptor (VEGF), bevacizumab and cetuximab a MoAB against epidermal growth factor receptor (EGFR) are establishing their role in a many cancers after making their mark in colorectal cancer. Sorafenib and sunitinib have success stories in renal carcinoma. The Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial has established sorafenib role in advanced hepatocellular carcinoma, while in gastrointestinal tumors; imatinib and sunitinib have proven role. At this point in time side effect profile of all these agents appears relatively safe however cost for developing countries remains an issue.

Original languageEnglish
Pages (from-to)398-405
Number of pages8
JournalJournal of the Pakistan Medical Association
Volume59
Issue number6
Publication statusPublished - 2009

Fingerprint

Hepatocellular Carcinoma
Monoclonal Antibodies
Neoplasms
Growth Factor Receptors
Clinical Protocols
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Developing Countries
Colorectal Neoplasms
Breast Neoplasms
Carcinoma
Kidney
Costs and Cost Analysis
Survival
Therapeutics
sorafenib
sunitinib
Bevacizumab
vascular factor
Cetuximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Old disease, new targets part-I, solid malignancies. / Kumar, Shiyam; Masood, Nehal; Shaikh, Asim Jamal.

In: Journal of the Pakistan Medical Association, Vol. 59, No. 6, 2009, p. 398-405.

Research output: Contribution to journalArticle

Kumar, Shiyam ; Masood, Nehal ; Shaikh, Asim Jamal. / Old disease, new targets part-I, solid malignancies. In: Journal of the Pakistan Medical Association. 2009 ; Vol. 59, No. 6. pp. 398-405.
@article{1e3b7d9d0d28479daa4712b4cd3c8d28,
title = "Old disease, new targets part-I, solid malignancies",
abstract = "Targeted agents are now an integral part of treatment regimens for some cancers. Trastuzumab is established in treatment of human epidermal receptor 2 (Her2) positive breast cancers, with improvements in both, the disease free and over all survival. Monoclonal antibody (MoAB) against vascular growth factor receptor (VEGF), bevacizumab and cetuximab a MoAB against epidermal growth factor receptor (EGFR) are establishing their role in a many cancers after making their mark in colorectal cancer. Sorafenib and sunitinib have success stories in renal carcinoma. The Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial has established sorafenib role in advanced hepatocellular carcinoma, while in gastrointestinal tumors; imatinib and sunitinib have proven role. At this point in time side effect profile of all these agents appears relatively safe however cost for developing countries remains an issue.",
author = "Shiyam Kumar and Nehal Masood and Shaikh, {Asim Jamal}",
year = "2009",
language = "English",
volume = "59",
pages = "398--405",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "6",

}

TY - JOUR

T1 - Old disease, new targets part-I, solid malignancies

AU - Kumar, Shiyam

AU - Masood, Nehal

AU - Shaikh, Asim Jamal

PY - 2009

Y1 - 2009

N2 - Targeted agents are now an integral part of treatment regimens for some cancers. Trastuzumab is established in treatment of human epidermal receptor 2 (Her2) positive breast cancers, with improvements in both, the disease free and over all survival. Monoclonal antibody (MoAB) against vascular growth factor receptor (VEGF), bevacizumab and cetuximab a MoAB against epidermal growth factor receptor (EGFR) are establishing their role in a many cancers after making their mark in colorectal cancer. Sorafenib and sunitinib have success stories in renal carcinoma. The Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial has established sorafenib role in advanced hepatocellular carcinoma, while in gastrointestinal tumors; imatinib and sunitinib have proven role. At this point in time side effect profile of all these agents appears relatively safe however cost for developing countries remains an issue.

AB - Targeted agents are now an integral part of treatment regimens for some cancers. Trastuzumab is established in treatment of human epidermal receptor 2 (Her2) positive breast cancers, with improvements in both, the disease free and over all survival. Monoclonal antibody (MoAB) against vascular growth factor receptor (VEGF), bevacizumab and cetuximab a MoAB against epidermal growth factor receptor (EGFR) are establishing their role in a many cancers after making their mark in colorectal cancer. Sorafenib and sunitinib have success stories in renal carcinoma. The Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial has established sorafenib role in advanced hepatocellular carcinoma, while in gastrointestinal tumors; imatinib and sunitinib have proven role. At this point in time side effect profile of all these agents appears relatively safe however cost for developing countries remains an issue.

UR - http://www.scopus.com/inward/record.url?scp=66949179702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949179702&partnerID=8YFLogxK

M3 - Article

C2 - 19534378

AN - SCOPUS:66949179702

VL - 59

SP - 398

EP - 405

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 6

ER -